{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT01985828",
            "orgStudyIdInfo": {
                "id": "5307"
            },
            "organization": {
                "fullName": "Advocate Health Care",
                "class": "OTHER"
            },
            "briefTitle": "CyberKnife\u00ae as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer",
            "officialTitle": "Prospective Evaluation of CyberKnife\u00ae as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "cyberknife-as-monotherapy-or-boost-sbrt-for-intermediate-or-high-risk-localized-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2021-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2013-11-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2021-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2013-04-12",
            "studyFirstSubmitQcDate": "2013-11-09",
            "studyFirstPostDateStruct": {
                "date": "2013-11-15",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2021-07-19",
            "lastUpdatePostDateStruct": {
                "date": "2021-07-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Arica Hirsch, MD",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Advocate Health Care"
            },
            "leadSponsor": {
                "name": "Advocate Health Care",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objective of this study is to document the effectiveness of Cyberknife stereotactic body radiotherapy (SBRT) in the treatment of intermediate and high-risk localized prostate cancer defined by biochemical Disease-Free Survival (bDFS), using Phoenix and American Society of Therapeutic Radiation and Oncology (ASTRO) definitions, at 5 years.\n\nDuring the prostate-specific antigen era, an ever-increasing percentage of men with prostate cancer have presented with clinically localized, potentially curable disease. Although conventional treatment options are potentially curative in selected patients, these treatments also have drawbacks, including the risk of negative long-term quality of life consequences and serious complications.\n\nThe CyberKnife\u00ae system is a type of radiation machine that uses a special system to precisely focus large doses of x-rays on the tumor. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal.\n\nIntermediate risk patients will be treated with either CyberKnife\u00ae Stereotactic Body Radiation Therapy (SBRT) monotherapy or CyberKnife\u00ae SBRT boost followed by Intensity Modulated Radiation Therapy (IMRT). High risk patients will be treated with CyberKnife\u00ae SBRT boost followed by IMRT. Treatment will last 4-7 days. Patients will complete the QOL questionnaires before treatment. Questionnaires will also be completed during follow-up visits at 1, 3 , 6, 12, 18, 24, 30 and 36 months then every 12 months until year 5."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Adenocarcinoma"
            ],
            "keywords": [
                "Prostate neoplasm",
                "Prostate Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 72,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Intermediate Risk",
                    "type": "EXPERIMENTAL",
                    "description": "Short term (4-6 months) androgen deprivation therapy (ADT) per current standard of care + CyberKnife 21 Gy (7 Gy x 3) and Prostate/SV Intensity Modulated radiation therapy (IMRT) 45-50.4 Gy\n\nOR\n\nShort term (4-6 months)androgen deprivation therapy + CyberKnife 36.35 Gray (7.27 Gray x 5)",
                    "interventionNames": [
                        "Radiation: CyberKnife",
                        "Other: Androgen Deprivation Therapy (ADT)",
                        "Radiation: Intensity Modulated radiation therapy (IMRT)"
                    ]
                },
                {
                    "label": "High Risk",
                    "type": "EXPERIMENTAL",
                    "description": "Short or Long term (6 months - 3 years) androgen deprivation therapy (ADT) + 45-50.4 Gy and Pelvis Intensity Modulated radiation therapy (IMRT) per current standard of care + 21 Gy (7 Gy x 3) CyberKnife boost",
                    "interventionNames": [
                        "Radiation: CyberKnife",
                        "Other: Androgen Deprivation Therapy (ADT)",
                        "Radiation: Intensity Modulated radiation therapy (IMRT)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "RADIATION",
                    "name": "CyberKnife",
                    "armGroupLabels": [
                        "High Risk",
                        "Intermediate Risk"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Androgen Deprivation Therapy (ADT)",
                    "armGroupLabels": [
                        "High Risk",
                        "Intermediate Risk"
                    ]
                },
                {
                    "type": "RADIATION",
                    "name": "Intensity Modulated radiation therapy (IMRT)",
                    "description": "Per current standard of care",
                    "armGroupLabels": [
                        "High Risk",
                        "Intermediate Risk"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Biochemical Disease-Free Survival (bDFS), using Phoenix and ASTRO definitions",
                    "timeFrame": "5 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Measure the rates of acute and late grade 3-5 gastrointestinal and genitourinary toxicity",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Measure local failure rates",
                    "description": "Measurement of local recurrence of prostate cancer",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Measure distant failure rates",
                    "description": "Measurement of distant metastasis rate",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Measure clinical disease-free survival rates",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Measure disease-specific survival rates",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Measure Overall Survival",
                    "timeFrame": "5 years"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Quality of life (QOL) in generic and organ-specific domains",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "* Patient must be \u2265 18 years of age.\n* Histologically proven prostate adenocarcinoma\n\n  * Gleason score 2-10 (reviewed by reference lab)\n  * Biopsy within one year of date of registration\n  * Clinical stage T1b-T4, N0-Nx, M0-Mx (AJCC 7th Edition)\n  * T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, CT, and/or MRI; see section 4.5)\n  * M-stage determined by physical exam, CT or MRI. Bone scan not required unless clinical findings suggest possible osseous metastases.\n* PSA \u2264 50 ng/ml, CBC, platelets, BUN, creatinine prior to treatment\n* Patients belonging in one of the following risk groups:\n\n  * Intermediate: CS T2b-c and Gleason \\<6 and PSA \u2264 10, or CS T1b-T2b, and Gleason 7 and PSA \u2264 10 ng/ml, or Gleason \\<6 and PSA 11-20 ng/ml\n  * High: CS T3-4, Gleason score \\>7and PSA\\<50\n* Prostate volume: \u2264 100 cc\n\n  * Determined using: volume = \u03c0/6 x length x height x width\n  * Measurement from MRI, CT or ultrasound prior to registration.\n* ECOG performance status 0-1\n* No prior prostatectomy or cryotherapy of the prostate\n* No prior radiotherapy to the prostate or lower pelvis\n* No implanted hardware or other material that would prohibit appropriate treatment planning or treatment delivery, in the investigator's opinion.\n* No chemotherapy for a malignancy in the last 5 years.\n* No history of an invasive malignancy (other than this prostate cancer, or basal or squamous skin cancers) in the last 5 years.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Arica Hirsch, MD",
                    "role": "CONTACT",
                    "phone": "847-723-8030"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Arica Hirsch, MD",
                    "affiliation": "Advocate Lutheran General Hospital",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Majid M Mohiuddin, MD",
                    "affiliation": "Advocate Lutheran General Hospital",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "Advocate Lutheran General Hospital",
                    "status": "RECRUITING",
                    "city": "Park Ridge",
                    "state": "Illinois",
                    "zip": "60068",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Arica Hirsch, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Arica Hirsch, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.01114,
                        "lon": -87.84062
                    }
                }
            ]
        }
    },
    "annotationSection": {
        "annotationModule": {
            "unpostedAnnotation": {
                "unpostedResponsibleParty": "Arica Hirsch, MD, Principal Investigator, Advocate Health Care",
                "unpostedEvents": [
                    {
                        "type": "RELEASE",
                        "date": "2024-06-21"
                    },
                    {
                        "type": "RESET",
                        "date": "2024-07-16"
                    }
                ]
            }
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "submissionTracking": {
                "estimatedResultsFirstSubmitDate": "2024-06-21",
                "submissionInfos": [
                    {
                        "releaseDate": "2024-06-21",
                        "resetDate": "2024-07-16"
                    }
                ]
            }
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3585",
                    "name": "Adenocarcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000728",
                    "term": "Androgens"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4059",
                    "name": "Androgens",
                    "asFound": "Percutaneous Coronary Intervention",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}